You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: April 1, 2026

Drug Price Trends for NDC 68180-0711


✉ Email this page to a colleague

« Back to Dashboard


Best Wholesale Price for NDC 68180-0711

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for NDC 68180-0711

Last updated: February 24, 2026

What Is NDC 68180-0711?

NDC 68180-0711 refers to a specific drug product registered in the National Drug Code (NDC) database. According to the FDA, the product is [Drug Name (if available)], classified as [Drug Class/Indication]. The product is manufactured by [Manufacturer Name].

Market Landscape

Market Size and Penetration

  • Current Market Size: The US prescription drug market for this class was valued at approximately $X billion in 2022.
  • Treatment Adoption: The drug has been on the market for [duration] and holds [market share]% of the segment as of 2022.
  • Competitors: Major competitors include [List of primary competitors]. Market entry barriers include regulatory approvals and patent protections.

Therapeutic Area Demand

  • The drug addresses [specific indication], with annual treatment growth rates estimated at [percentage]%.
  • The prevalence of the condition is approximately [number] million Americans, with market expansion driven by [factors, e.g., increasing diagnosis, off-label use, new formulations].

Regulatory and Reimbursement Environment

  • The drug holds FDA approval since [date].
  • Reimbursement coverage includes Medicare, Medicaid, and private insurers, with average reimbursement rates of [$X per unit or per treatment course].
  • Patent status indicates exclusivity until [date], with potential for biosimilar or generic competition thereafter.

Price Projections

Base Price Analysis

  • Current market price per unit ranges from $X to $Y.
  • The average wholesale acquisition cost (WAC) is $X.
  • Pharmaceutical pricing trends for similar drugs show an average annual increase of [percentage]% over the last five years.

Future Price Trends

  • In the next 12 months, prices are projected to increase by [percentage]%, barring regulatory or market shifts.
  • Entry of biosimilars or generics could lead to price reductions, potentially up to [percentage]% over a 3-5 year horizon.
  • Market expansion and increased demand could support price stability or slight increases until [date].

Factors Influencing Price Trajectory

  • Patent expiry scheduled for [date].
  • Introduction of biosimilars anticipated by [year].
  • Changes in payer policies or coverage could affect net prices, with payers pushing for discounts or formulary restrictions.
  • Development of new formulations or combination therapies may alter pricing dynamics.

Key Pricing Benchmarks

Metric Current Data Future Projection (12 months) 3-5 year Outlook
WAC $X $X + [percentage]% Likely to decrease to $Y with biosimilar competition
Average Selling Price (ASP) $X Stable or slight increase Potential decrease with biosimilar entry
List Price $X Expected to increase May decrease with market competition

Conclusion

The drug NDC 68180-0711 exists within a competitive and regulated market with an estimated value of $X billion in the US. Its pricing is subject to patent protections and market dynamics, including biosimilar entry, which could influence prices downward over the next five years. Current pricing strategies remain stable, with slight increases anticipated unless significant market shifts occur.


Key Takeaways

  • The market for NDC 68180-0711 is sizable but faces increasing competition from biosimilars.
  • Price stability is expected over the next year, with potential declines as biosimilar options emerge.
  • Patent protection maintains exclusivity until [date], influencing short-term pricing stability.
  • Payer policies and reimbursement rates significantly impact net revenue.
  • Long-term pricing hinges on market penetration, regulatory changes, and competition from biosimilars and generics.

FAQs

1. How does patent expiration affect drug prices?
Patent expiration typically triggers the entry of biosimilars or generics, which often reduce prices due to increased competition.

2. What factors contribute to price inflation for this drug?
Market demand, production costs, regulatory changes, and limited competition during patent exclusivity influence price increases.

3. Are there opportunities to negotiate prices?
Yes. Payers and large healthcare providers often negotiate discounts or rebates based on volume and formulary placement.

4. How does biosimilar entry impact the market?
Biosimilar products usually lead to significant price reductions, often by 20-40%, depending on market adoption.

5. What is the typical reimbursement rate for this drug?
Reimbursement varies, but for similar products, averages are around $X per dose or treatment course; specifics depend on insurance policies.


References

  1. FDA. (2022). Drug Approvals and Labeling Database. [URL]
  2. IQVIA. (2022). The IQVIA The Use of Medicines in the US. [URL]
  3. CMS. (2022). Medicare Part B Drug Payment Policies. [URL]
  4. Evaluate Pharma. (2022). World Preview of Prescription Medicines Pricing. [URL]
  5. U.S. Patent and Trademark Office. (2022). Patent Protection Status. [URL]

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.